NASONEX(R) Now Approved In Japan For The Treatment Of Allergic Rhinitis In Adult Patients

Schering-Plough Corporation (NYSE: SGP) announced that Schering-Plough K.K., the company’s country operation in Japan, has received marketing approval for NASONEX(R) (mometasone furoate monohydrate) Nasal Spray 50mcg for the treatment of allergic rhinitis in adult patients.(1) NASONEX is an intranasal steroid that significantly improves nasal allergy symptoms when taken once each day. NASONEX is the first intranasal steroid to be approved in Japan for once-daily administration.

More: continued here

Filed under: Ear, Nose and Throat on July 25th, 2008